# SL-28 for Advanced Solid Tumours

> **NCT07341737** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Life Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Head & Neck Cancer
- Pancreas Carcinoma
- Pancreas Cancer, Metastatic
- Lung Adenocarcinoma
- Lung Cancer (NSCLC)
- Lung Cancer (Non-Small Cell)
- Esophageal Cancer
- Stomach (Gastric) Cancer
- Liver Cancer
- Intestinal Cancer
- Bladder Cancer
- Renal Cancer
- Prostate Cancer
- Melanoma (Skin Cancer)
- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** SL-28
- **BIOLOGICAL:** SL-28
- **BIOLOGICAL:** SL-28

## Key facts

- **NCT ID:** NCT07341737
- **Lead sponsor:** Second Life Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07341737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07341737, "SL-28 for Advanced Solid Tumours". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT07341737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*